#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "Alzheimer’s disease and the autophagic-lysosomal system"
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Sandra Spalek"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns"
DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns"
DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns"
# DEFINE NAMESPACE FB           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/80171ae62cf43aa1fc8a6c326b94537ab342458c/external/fb-names.belns"
DEFINE NAMESPACE HBP            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/cf4d8bb88754f036b943b4d94ad96e103dcb7149/export/hbp-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns"
DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/73688d6dc24e309fca59a1340dc9ee971e9f3baa/external/hgnc.genefamily-names.belns"
DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/a5b84013a08880975ca84f40999e4404b14a97e2/external/go-names.belns"
DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns"
DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns"
DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns"
DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns"
DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns"
DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns"
DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns"

# Namespaces hosted on https://arty.scai.fraunhofer.de/artifactory/bel/namespace
# ------------------------------------------------------------------------------
DEFINE NAMESPACE CTO            AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns"
DEFINE NAMESPACE DO             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns"
DEFINE NAMESPACE HP             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns"
DEFINE NAMESPACE SCOMP          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns"
DEFINE NAMESPACE SFAM           AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############

# Add statements below this comment

SET Citation = {"PubMed","29758300"}

SET Evidence = "Since Nixon and colleagues first reported the pathological evidence
of defective macroautophagy in EM images in the AD brain, similar
observations have been made in cellular and animal models of AD [2,3,7,14]"
path(MESH:"Alzheimer Disease") neg bp(GO:macroautophagy)

SET Evidence = "Robust AV accumulation in dystrophic neurites from biopsy
tissues from patients with AD implicate a compromised state of autophagic flux"
# AV: autophagosome
path(MESH:"Alzheimer Disease") -> complex(a(HBP:"dystrophic neurite"),a(GO:autophagosome))
path(MESH:"Alzheimer Disease") neg bp(GO:autophagy)

SET Evidence = "Other studies have also demonstrated the accumulation
of autolysosomes in the AD brain and experimentally when lysosomal
proteolysis is compromised via genetic knockdown of specific cathepsins
or use of pharmacological inhibition of lysosomes [2,3,15]"
SET MeSHAnatomy = "Brain"
path(MESH:"Alzheimer Disease") pos a(GO:autolysosome)
bp(GO:"lysosomal protein catabolic process") -| a(GO:autolysosome)
UNSET MeSHAnatomy

SET Evidence = "Such evidence of lysosomal proteolytic failure in AD brain further
strengthens the concept that impaired macroautophagy in AD is a critical event"
SET MeSHAnatomy = "Brain"
path(MESH:"Alzheimer Disease") neg bp(GO:"lysosomal protein catabolic process")
UNSET MeSHAnatomy

SET Evidence = "Defects in macroautophagy in AD are supported by additional lines of evidence"
path(MESH:"Alzheimer Disease") neg bp(GO:macroautophagy)

SET Evidence = "For example, levels of Beclin 1, a key component of the
class III type phosphoinositide 3-kinase/VPS34 complex essential to the
pre-autophagosomal structure (PAS), has been suggested to be reduced
in AD brains [16,17], with Rohn et al. demonstrating the cleavage of
Beclin 1 by caspase-3 in the AD brain and colocalization of the cleaved product with NFTs [16]."
SET MeSHAnatomy = "Brain"
complex(GO:"phosphatidylinositol 3-kinase complex, class III") hasComponent p(HGNC:BECN1)
path(MESH:"Alzheimer Disease") neg p(HGNC:BECN1)
p(HGNC:CASP3) -> p(HGNC:BECN1,frag("?"))
p(HGNC:BECN1,frag("?")) -- a(GO:"neurofibrillary tangle")
UNSET MeSHAnatomy

SET Evidence = "Furthermore, presenilin-1, the most common
mutation associated with early-onset familial AD (FAD), plays an essential
role in calcium homeostasis and maintaining acidic lysosomal
pH, with FAD-associated mutations disrupting calcium-dependent
vATPase function in lysosomes [7,18–20]"
p(HGNC:PSEN1,var("?")) -- path(MESH:"Alzheimer Disease")
p(HGNC:PSEN1) -- bp(GO:"calcium ion homeostasis")
p(HGNC:PSEN1) -- bp(GO:"regulation of lysosomal lumen pH")
p(HGNC:PSEN1,var("?")) -| act(a(MESH:"Vacuolar Proton-Translocating ATPases"))
a(CHEBI:"calcium ion") -> act(a(MESH:"Vacuolar Proton-Translocating ATPases"))

SET Evidence = "Recently, a comprehensive investigation utilizing gene expression analysis of the
hippocampal region (CA1) of patients with Alzheimer’s disease identified
that autophagosome formation and lysosomal biogenesis genes
were upregulated at early stages of AD [21]"
SET MeSHAnatomy = "CA1 Region, Hippocampal"
path(MESH:"Alzheimer Disease") -> a(GO:lysosome)
path(MESH:"Alzheimer Disease") -> a(GO:autophagosome)
UNSET MeSHAnatomy

SET Evidence = "Even early autophagic activation may become impaired due to
progressively diminishing lysosomal clearance of substrates."
bp(GO:"lysosomal protein catabolic process") pos bp(GO:autophagy)

SET Evidence = "Maintenance of neuronal macroautophagy can counteract AD pathology [22,23]."
SET MeSHAnatomy = "Neurons"
bp(GO:macroautophagy) neg path(MESH:"Alzheimer Disease")
UNSET MeSHAnatomy

SET Evidence = "For instance, rapamycin, an inhibitor of the Ser/Thr
protein kinase mammalian target of rapamycin (mTOR), improves
cognitive function and reduces Aβ in AD mouse model by enhancing autophagic flux [23]."
a(CHEBI:sirolimus) -| act(p(HGNC:MTOR))
a(CHEBI:sirolimus) -> bp(GO:cognition)
a(CHEBI:sirolimus) -| a(CHEBI:"amyloid-beta")
a(CHEBI:sirolimus) -> bp(GO:autophagy)

SET Evidence = "The presence of aberrant protein aggregates is common to neurodegenerative diseases"
a(HBP:"protein aggregates") pos path(MESH:"Neurodegenerative Diseases")

SET Evidence = "Accumulation of misfolded proteins and damaged
organelles is highly detrimental for neuronal homeostasis and survival."
p(MESH:Proteins,pmod(HBP:misfolding)) -| bp(GO:"neuron cellular homeostasis")
p(MESH:Proteins,pmod(HBP:misfolding)) -| a(MESH:Neurons)

SET Evidence = "Although the UPS is accountable for the degradation of up to 80–90% of
proteins, misfolded proteins and aggregates are too large to be processed
through the proteasome barrel and can impede UPS function by
physical occlusion, leaving autophagic-lysosomal breakdown as the
only effective pathway to clear these proteins [25,26]"
bp(GO:autophagy) -> deg(p(MESH:Proteins,pmod(HBP:misfolding)) )
bp(GO:autophagy) -> deg(a(HBP:"protein aggregates"))

SET Evidence = "Impairment in the UPS is cardinal to the development of neurodegeneration, in part
because of its reciprocal interplay with protein aggregation"
bp(GO:"proteasome-mediated ubiquitin-dependent protein catabolic process") neg path(HBP:Neurodegeneration)

SET Evidence = "For instance, phosphorylated insoluble tau proteins dampen 26S proteasome
activity, while activation of the UPS attenuates tauopathy [27]"
p(HGNC:MAPT,pmod(Ph)) -| act(complex(GO:"proteasome complex"))
bp(GO:"proteasome-mediated ubiquitin-dependent protein catabolic process") -| path(MESH:Tauopathies)

SET Evidence = "With neurons profoundly relying on macroautophagy for clearance of toxic
protein aggregates, impairment in the proteolytic systems ultimately
results in progressive neuronal death, a common feature in several
neurodegenerative diseases [27]."
bp(GO:macroautophagy) -> deg(a(HBP:"protein aggregates"))
bp(GO:proteolysis) -| bp(GO:"neuron death")
bp(GO:"neuron death") -- path(MESH:"Neurodegenerative Diseases")

SET Evidence = "Defective chaperone-mediated autophagy
(CMA), a type of autophagy that targets proteins with a specific
KFERQ-like motif recognizable to its chaperones, plays a significant role
in aggregate formation of disease-related proteins [28]."
bp(GO:"chaperone-mediated autophagy") -| a(HBP:"protein aggregates")

SET Evidence = "While misfolding of Aβ peptide and hyperphosphorylation of tau are recognized
as pathogenic mechanisms of AD, accumulation of α-synuclein,
which is recognized more as a risk factor for Parkinson’s disease
(PD), also plays a pathological role in AD [29]."
p(MESH:"Amyloid beta-Peptides",pmod(HBP:misfolding)) -> path(MESH:"Alzheimer Disease")
p(HGNC:MAPT,pmod(HBP:hyperphosphorylation)) -> path(MESH:"Alzheimer Disease")
p(HGNC:SNCA) pos path(MESH:"Alzheimer Disease")
p(HGNC:SNCA) -> path(MESH:"Parkinson Disease")

SET Evidence = "Formation of amyloid β (Aβ) plaques is one of the most notable
hallmarks in AD pathology [30]"
path(MESH:"Plaque, Amyloid") pos path(MESH:"Parkinson Disease")

SET Evidence = "Aβ peptides originate from the transmembrane protein amyloid precursor protein (APP) which undergoes
sequential cleavage via two distinct pathways by the enzyme complexes β- and γ-secretase [31]"
p(HGNC:APP) -> a(MESH:"Amyloid beta-Peptides")
complex(GO:"gamma-secretase complex") -> p(HGNC:APP,frag("?"))
p(HGNC:BACE1) -> p(HGNC:APP,frag("?"))

SET Evidence = "Increased Aβ generation and accumulation in lysosomes suggest
that Aβ metabolism, at least partially, is regulated by macroautophagy [3,14,32–34]."
SET CellStructure = "Lysosomes"
bp(GO:macroautophagy) reg a(CHEBI:"amyloid-beta")
UNSET CellStructure

SET Evidence = "For instance, while accumulation of Aβ activates the mTOR signaling pathway and subsequently blocks macroautophagy,
rapamycin reduces the Aβ load by enhancing macroautophagy [32]"
a(CHEBI:"amyloid-beta") pos act(complex(GO:"TOR complex"))
a(CHEBI:"amyloid-beta") neg bp(GO:macroautophagy)
a(CHEBI:sirolimus) -| a(CHEBI:"amyloid-beta")
a(CHEBI:sirolimus) -> bp(GO:macroautophagy)

SET Evidence = "In line with this, reduced Beclin 1 levels, as seen in AD models [16],
increase the levels of intracellular and extracellular Aβ peptides, supporting
the role of macroautophagy in the generation and degradation of Aβ [33,35]."
path(MESH:"Alzheimer Disease") -| p(HGNC:BECN1)
p(HGNC:BECN1) -| a(MESH:"Amyloid beta-Peptides")
bp(GO:macroautophagy) -> deg(a(CHEBI:"amyloid-beta"))
bp(GO:macroautophagy) reg a(CHEBI:"amyloid-beta")

SET Evidence = "These results may be attributed to coincidental evidence of the involvement of Beclin
1 in VPS34-mediated trafficking pathways including macroautophagy
and endocytosis [37], both of which are pronouncedly affected in AD pathology [38]"
path(MESH:"Alzheimer Disease") neg bp(GO:macroautophagy)
path(MESH:"Alzheimer Disease") neg bp(GO:endocytosis)
p(HGNC:BECN1) -- bp(GO:macroautophagy)
p(HGNC:BECN1) -- bp(GO:endocytosis)

SET Evidence = "Compromised macroautophagy, via the genetic suppression
of Atg7, leads to the blockade of Aβ secretion and contributes
to the subsequent diminution in extracellular Aβ plaque load"
p(HGNC:ATG7) -> bp(GO:macroautophagy)
bp(GO:macroautophagy) -> sec(a(CHEBI:"amyloid-beta"))
bp(GO:macroautophagy) -> path(MESH:"Plaque, Amyloid")

SET Evidence = "This inhibition of Aβ secretion during macroautophagy deficiency results in
aberrant cytosolic accumulation of Aβ, which ultimately evokes neurodegeneration accompanied with memory loss."
bp(GO:macroautophagy) -> sec(a(CHEBI:"amyloid-beta"))
sec(a(CHEBI:"amyloid-beta")) -| path(HBP:Neurodegeneration)
sec(a(CHEBI:"amyloid-beta")) -> bp(GO:memory)

SET Evidence = "Tau serves an important function by enabling microtubules to connect with cytoskeletal
components and facilitates anterograde and retrograde axonal transport of vesicles and organelles [39]."
p(HGNC:MAPT) -> complex(a(GO:microtubule),a(GO:cytoskeleton))
p(HGNC:MAPT) -> bp(GO:"anterograde axonal protein transport")
p(HGNC:MAPT) -> bp(GO:"retrograde axonal protein transport")

SET Evidence = "However, when tau becomes hyperphosphorylated, it detaches from microtubules and aggregates, resulting
in depolymerization of microtubules and formation of insoluble tau deposits [40]"
p(HGNC:MAPT,pmod(HBP:hyperphosphorylation)) -| complex(a(GO:microtubule),p(HGNC:MAPT))
p(HGNC:MAPT,pmod(HBP:hyperphosphorylation)) -> a(HBP:"Tau aggregates")
p(HGNC:MAPT,pmod(HBP:hyperphosphorylation)) -> bp(GO:"microtubule depolymerization")

SET Evidence = "Dysregulation of tau proteins can produce a spectrum of neurodegenerative
diseases or tauopathies characterized by dementia and tau deposition, including AD, frontotemporal dementia (FTD), Niemann-
Pick disease, corticobasal degeneration (CBD), tangle-only dementia (TOD) and progressive supranuclear palsy (PSP)."
p(HGNC:MAPT) -- path(MESH:Tauopathies)
path(MESH:Tauopathies) -- path(MESH:Dementia)
p(HGNC:MAPT) -- path(MESH:"Alzheimer Disease")
p(HGNC:MAPT) -- path(MESH:"Frontotemporal Dementia")
p(HGNC:MAPT) -- path(MESH:"Niemann-Pick Diseases")
p(HGNC:MAPT) -- path(MESH:"Supranuclear Palsy, Progressive")

SET Evidence = "Tau phosphorylation, the major disease-related post-translational modification, is highly regulated
by glycogen synthase kinase-3β (GSK-3β), cyclin-dependent kinase
5 (CDK5), mitogen-activated protein kinase (MAPK) and other kinases."
p(HGNC:GSK3B) -> p(HGNC:MAPT,pmod(Ph))
p(HGNC:CDK5) -> p(HGNC:MAPT,pmod(Ph))
p(FPLX:MAPK) -> p(HGNC:MAPT,pmod(Ph))

SET Evidence = "Abnormal phosphorylation and truncation of tau are hallmarks
of AD pathology and are targets of proteasome and autophagy pathways [27,44,45]."
p(HGNC:MAPT,pmod(Ph)) -> path(MESH:"Alzheimer Disease")
complex(GO:"proteasome complex") -- p(HGNC:MAPT,pmod(Ph))
bp(GO:autophagy) -- p(HGNC:MAPT,pmod(Ph))

SET Evidence = "Tau aggregates can be targeted by two protein clearance pathways,
the UPS and the A-LS, with the latter pathway encompassing microautophagy,CMA and macroautophagy."
# A-LS: autophagic-lysosomal system
a(HBP:"Tau aggregates") -- bp(GO:"proteasome-mediated ubiquitin-dependent protein catabolic process")
a(HBP:"Tau aggregates") -- bp(GO:autophagy)

SET Evidence = "Evidence suggests that CMA can degrade tau via the chaperone heat shock cognate of 70 kDa
(Hsc70), which recognizes KFERQ-like motifs and transfers its substrates via LAMP-2 into the lysosome [47]"
bp(GO:"chaperone-mediated autophagy") -> deg(p(HGNC:MAPT))
p(HGNC:HSPA8) -> deg(p(HGNC:MAPT))
composite(p(HGNC:LAMP2),p(HGNC:HSPA8)) -> tloc(p(HGNC:MAPT),fromLoc(GO:cytosol),toLoc(GO:lysosome))

SET Evidence = "Wang et al., using an N2a neuroblastoma cell line that expresses the repeat domain of tau with an
FTD-17 mutation (TauRDΔK280), has demonstrated that tau aggregates can be degraded by macroautophagy [48]"
bp(GO:macroautophagy) -> deg(a(HBP:"Tau aggregates"))

SET Evidence = "Lastly, macroautophagy, but not UPS or CMA can clear protein aggregates."
bp(GO:macroautophagy) -> deg(a(HBP:"protein aggregates"))

SET Evidence = "NBR1 colocalizes with tau and has primary sequence domains for binding [52]."
p(HGNC:NBR1) -- p(HGNC:MAPT)

SET Evidence = "Evidence that p62 facilitates tau degradation has been demonstrated in several studies where
p62 colocalized with tau in NFTs from AD patients [53]."
p(HGNC:SQSTM1) -> deg(p(HGNC:MAPT))

SET Evidence = "For example, Babu et al. has shown that p62−/− knockout mice have increased levels
of hyperphosphorylated tau, reduction of synaptophysin and changes in short term memory compared to p62+/− [54]"
p(HGNC:SQSTM1) -| p(HGNC:MAPT,pmod(HBP:hyperphosphorylation))
p(HGNC:SQSTM1) -> p(HGNC:SYP)
p(HGNC:SQSTM1) reg bp(GO:"short-term memory")

SET Evidence = "While AD is generally considered a disorder with two proteinopathies,
other protein aggregates are also seen in AD, like α-synuclein"
path(MESH:"Alzheimer Disease") -- a(HBP:"alpha-synuclein aggregates")

SET Evidence = "Recent clinical and immunohistochemistry studies demonstrate the
contribution of α-synuclein in the development of AD pathology"
p(HGNC:SNCA) -> path(MESH:"Alzheimer Disease")

SET Evidence = "Misfolded α-synuclein proteins form insoluble oligomers, which in turn
lead to the cascade of pathogenic neurotoxicity-induced responses such
as neuroinflammation and cell death [55]"
p(HGNC:SNCA,pmod(HBP:misfolding)) -> a(HBP:"alpha-synuclein oligomers")
a(HBP:"alpha-synuclein oligomers") -> path(HBP:neuroinflammation)
a(HBP:"alpha-synuclein oligomers") -> bp(GO:"cell death")

SET Evidence = "First identified as a nonamyloid component of Aβ plaques in the AD brain, α-synuclein aggregates
are detected in the majority of the brains of patients with AD [56,57]."
SET MeSHAnatomy = "Brain"
path(MESH:"Alzheimer Disease") pos a(HBP:"alpha-synuclein aggregates")
UNSET MeSHAnatomy

SET Evidence = "Since the initial finding of proteasome-dependent degradation
of α-synuclein [58], significant efforts have been made to
clarify the modes of α-synuclein metabolism"
complex(GO:"proteasome complex") -> deg(p(HGNC:SNCA))

SET Evidence = "These experimental differences may be attributed to the intricate interplay
between the UPS and autophagy, as α-synuclein is degraded by both proteolytic systems [62,63]."
bp(GO:autophagy) -> deg(p(HGNC:SNCA))
bp(GO:"proteasome-mediated ubiquitin-dependent protein catabolic process") -> deg(p(HGNC:SNCA))

SET Evidence = "Cuervo et al. have revealed a distinct
interaction of wild-type and mutant α-synuclein proteins with CMA [64]"
bp(GO:"chaperone-mediated autophagy") -- p(HGNC:SNCA)
bp(GO:"chaperone-mediated autophagy") -- p(HGNC:SNCA,var("?"))

SET Evidence = "While wild-type α-synuclein protein efficiently
clears via CMA, the pathogenic A53T and A30P variants remain
bound to LAMP-2, blocking lysosomal degradation by preventing
binding of other substrate complexes to the receptor [64]."
bp(GO:"chaperone-mediated autophagy") -> deg(p(HGNC:SNCA))
complex(p(HGNC:SNCA,var("p.Ala53Thr")),p(HGNC:LAMP2)) -| bp(GO:"lysosomal protein catabolic process")
complex(p(HGNC:SNCA,var("p.Ala30Pro")),p(HGNC:LAMP2)) -| bp(GO:"lysosomal protein catabolic process")

SET Evidence = "Another common proteinopathy occurs from the misfolding of TARDNA
binding protein 43 kDa (TDP-43), which is primarily seen in
amyotrophic lateral sclerosis (ALS) and FTD [67]"
p(HGNC:TARDBP,pmod(HBP:misfolding)) pos path(MESH:"Amyotrophic Lateral Sclerosis")
p(HGNC:TARDBP,pmod(HBP:misfolding)) pos path(MESH:"Frontotemporal Dementia")

SET Evidence = "Although exact relations remain
unknown, it was reported that Aβ can induce a cascade that results
in phosphorylation and subsequent deposition of TDP-43 in the cytosol [70]"
a(CHEBI:"amyloid-beta") -> p(HGNC:TARDBP,pmod(Ph))
SET MeSHAnatomy = "Cytosol"
a(CHEBI:"amyloid-beta") -> p(HGNC:TARDBP)
UNSET MeSHAnatomy

SET Evidence = "In addition to their structural role in membranes, lipids are essential
in the maintenance of cellular energy homeostasis as well as regulation of intracellular signaling pathways"
a(CHEBI:lipid) reg bp(GO:"energy homeostasis")
a(CHEBI:lipid) reg bp(GO:"intracellular signal transduction")

SET Evidence = "Cytosolic lipids are stored as triglycerides in lipid droplets and are hydrolyzed into fatty acid for
energy under nutrient starvation"
path(MESH:Starvation) -> rxn(reactants(a(CHEBI:lipid)),products(a(CHEBI:"fatty acid")))

SET Evidence = "Decreased triglyceride breakdown upon macroautophagy
inhibition and impairment in macroautophagy by lipid
supplementation demonstrates reciprocally interrelated regulation of autophagy and lipids [72]"
bp(GO:macroautophagy) -> deg(a(CHEBI:triglyceride))
a(CHEBI:lipid) reg bp(GO:macroautophagy)

SET Evidence = "Decreased autophagy in the diseased brain may contribute to aberrant
lipid accumulation that occurs along with an increased incidence of the
metabolic syndrome in aged humans [76]"
bp(GO:autophagy) -| a(CHEBI:lipid)

SET Evidence = "While autophagic-lysosomal degradation is more commonly associated
with protein degradation, it serves to degrade all cellular material including carbohydrates and lipids."
bp(GO:autophagy) -> deg(a(CHEBI:lipid))
bp(GO:autophagy) -> deg(a(CHEBI:carbohydrate))

SET Evidence = "Lipid biology can also impact proteinopathy, with strong evidence
that Aβ metabolism is modulated by lipids"
a(CHEBI:lipid) reg bp(GO:"amyloid-beta metabolic process")

SET Evidence = "For instance, ApoE4–an important determinant of cholesterol metabolism
and the strongest genetic risk factor for sporadic AD – regulates Aβ degradation [77]."
g(HBP:"APOE e4") -> bp(GO:"cholesterol metabolic process")
g(HBP:"APOE e4") -> path(MESH:"Alzheimer Disease")
g(HBP:"APOE e4") reg deg(a(CHEBI:"amyloid-beta"))

SET Evidence = "Cellular cholesterol can directly impact the level of
Aβ, as decreases in cholesterol levels inhibit the generation of Aβ
peptides through direct modulation of γ-secretase activity [78,79]."
a(CHEBI:cholesterol) -> a(MESH:"Amyloid beta-Peptides")
a(CHEBI:cholesterol) reg act(complex(GO:"gamma-secretase complex"))

SET Evidence = "Sphingolipids are also strongly implicated in AD pathology, with upregulated
levels of ceramide, a key component in sphingolipid metabolism,
detected in the early phase of AD [80]."
a(CHEBI:ceramide) pos path(MESH:"Alzheimer Disease")

SET Evidence = "The finding of reduced Aβ generation when conversion of sphingomyelin
to ceramide is blocked further substantiates the crucial involvement
of sphingolipids in Aβ metabolism through modulation of γ-secretase [81,82]"
rxn(reactants(a(MESH:Sphingomyelins)),products(a(CHEBI:ceramide))) -> a(CHEBI:"amyloid-beta")
a(CHEBI:sphingolipid) reg act(complex(GO:"gamma-secretase complex"))

SET Evidence = "Cytosolic tau is highest in density in
membrane-rich axons and growth cones where lipid interaction with
cytosolic tau may contribute to fibrillary tau aggregation [84]."
SET MeSHAnatomy = "Cytosol"
complex(p(HGNC:MAPT),a(CHEBI:lipid)) -> a(HBP:"Tau aggregates")
UNSET MeSHAnatomy

SET Evidence = "Furthermore, the membrane bilayer lipid can influence protein aggregation
and subsequent tau pathology, with recent studies showing that tau
binds to the membrane, which has subsequent effects on the formation of fibrillary tau aggregates [85,86]."
complex(a(MESH:"Lipid Bilayers"),p(HGNC:MAPT)) -- a(HBP:"Tau aggregates")

SET Evidence = "In addition to the direct modulation
of protein generation, lipids can also influence the levels of proteins
through autophagic clearance; for instance, increasing lipid contents
has been shown to impair autophagy [72]."
a(CHEBI:lipid) neg bp(GO:autophagy)

SET Evidence = "Modulation of mTOR can influence the levels of tau,
with upregulation increasing tau phosphorylation and accumulation by
reducing autophagic clearance [87], and conversely, pharmacological
treatment with rapamycin reducing tau levels and rescuing motor
deficits in the Tau P301S mice [53]"
p(HGNC:MTOR) pos p(HGNC:MAPT,pmod(Ph))
p(HGNC:MTOR) neg bp(GO:autophagy)
a(CHEBI:sirolimus) -| p(HGNC:MAPT)
a(CHEBI:sirolimus) -> bp(GO:"motor behavior")

SET Evidence = "For instance, adenosine monophosphate-
activated protein kinase (AMPK) phosphorylates ULK1 and
inactivates mTOR through the raptor and tuberous sclerosis complex (TSC2)."
p(FPLX:AMPK) -> p(HGNC:ULK1,pmod(Ph))
composite(p(FPLX:AMPK),p(HGNC:TSC2)) -| act(p(HGNC:MTOR))

SET Evidence = "A recent study has demonstrated that activation of AMPKα1
enhances tau phosphorylation, while inhibition reduces tau phosphorylation
at Ser-262, an epitope that is increased in early stages of AD,
which promotes the autophagic degradation of tau [87]"
p(HGNC:PRKAA1) => p(HGNC:MAPT,pmod(Ph,Ser,262))
p(HGNC:MAPT,pmod(Ph,Ser,262)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT,pmod(Ph,Ser,262)) -> bp(GO:autophagy)
bp(GO:autophagy) -> deg(p(HGNC:MAPT))

SET Evidence = "Another modulator of A-LS implicated in AD pathology is transcription
factor EB (TFEB), a master regulator of lysosome biogenesis"
p(HGNC:TFEB) reg a(GO:lysosome)
p(HGNC:TFEB) reg bp(GO:autophagy)
p(HGNC:TFEB) -- path(MESH:"Alzheimer Disease")

SET Evidence = "TFEB at normal state is phosphorylated by mTOR complex 1, which inhibits its activity"
p(HGNC:TFEB,pmod(Ph)) -| act(p(HGNC:TFEB))

SET Evidence = "Under starvation or stress, TFEB translocates to the
nucleus and binds the CRE element to promote expression of macroautophagy
and lysosomal genes [88]."
path(MESH:Starvation) -> tloc(p(HGNC:TFEB),fromLoc(GO:cytosol),toLoc(GO:nucleus))
path(MESH:Starvation) -> complex(p(INTERPRO:"cAMP response element binding (CREB) protein"),p(HGNC:TFEB))
bp(GO:"cellular response to stress") -> tloc(p(HGNC:TFEB),fromLoc(GO:cytosol),toLoc(GO:nucleus))
bp(GO:"cellular response to stress") -> complex(p(INTERPRO:"cAMP response element binding (CREB) protein"),p(HGNC:TFEB))
complex(p(INTERPRO:"cAMP response element binding (CREB) protein"),p(HGNC:TFEB)) -> bp(GO:macroautophagy)
complex(p(INTERPRO:"cAMP response element binding (CREB) protein"),p(HGNC:TFEB)) -> a(GO:lysosome)

SET Evidence = "TFEB has been shown to effectively clear phosphorylated tau proteins through A-LS, resulting in
ameliorated neuronal loss and neuroinflammation, as well as improved cognitive performance [89]."
p(HGNC:TFEB) -> bp(GO:autophagy)
p(HGNC:TFEB) -> deg(p(HGNC:MAPT,pmod(Ph)))
bp(GO:autophagy) -> deg(p(HGNC:MAPT,pmod(Ph)))
deg(p(HGNC:MAPT,pmod(Ph))) -| bp(GO:"neuron death")
deg(p(HGNC:MAPT,pmod(Ph))) -| path(HBP:neuroinflammation)
deg(p(HGNC:MAPT,pmod(Ph))) -> bp(GO:cognition)

SET Evidence = "Activation of PTEN, another inducer of macroautophagy, by TFEB is
indispensable for this TFEB-mediated increase in macroautophagy [89]"
p(HGNC:TFEB) -> act(p(HGNC:PTEN))
p(HGNC:PTEN) -> bp(GO:macroautophagy)
composite(p(HGNC:PTEN),p(HGNC:TFEB)) -> bp(GO:macroautophagy)

SET Evidence = "Multiple large-scale GWAS demonstrate that variants of PICALM
(phosphatidylinositol-L-binding clathrin assembly protein involved in
endocytosis) are significantly associated with AD [90,93,94]."
p(HGNC:PICALM,var("?")) -- path(MESH:"Alzheimer Disease")

SET Evidence = "Overexpression of PICALM in APP/PS1 mice substantially
elevates Aβ levels, whereas knockdown reduces the Aβ plaque load, respectively [98]"
p(HGNC:PICALM) pos a(CHEBI:"amyloid-beta")
p(HGNC:PICALM) -> path(MESH:"Plaque, Amyloid")

SET Evidence = "A recent line of work revealed Aβ-promoting function
of PICALM by demonstrating that PICALM depletion decreased Aβ
generation through disrupting clathrin-mediated endocytosis and internalization
of γ-secretase [99,100]."
p(HGNC:PICALM) -> a(CHEBI:"amyloid-beta")
p(HGNC:PICALM) -> bp(GO:"clathrin-dependent endocytosis")
p(HGNC:PICALM) -> tloc(complex(GO:"gamma-secretase complex"),fromLoc(GO:"extracellular space"),toLoc(GO:intracellular))

SET Evidence = "PICALM may also promote amyloid
clearance from the brain by internalizing Aβ into endothelial cells
and ultimately into to the bloodstream [101]"
p(HGNC:PICALM) -> tloc(a(CHEBI:"amyloid-beta"),fromLoc(MESH:"Endothelial Cells"),toLoc(MESH:Blood))

SET Evidence = "However, recent work provides direct evidence that PICALM can also
modulate macroautophagy, via its role in SNARE endocytosis to clear tau aggregates [102]."
p(HGNC:PICALM) reg bp(GO:macroautophagy)
p(HGNC:PICALM) -> tloc(complex(GO:"SNARE complex"),fromLoc(GO:"extracellular space"),toLoc(GO:intracellular))
tloc(complex(GO:"SNARE complex"),fromLoc(GO:"extracellular space"),toLoc(GO:intracellular)) -> deg(a(HBP:"Tau aggregates"))

SET Evidence = "BIN1 is involved in the endocytosis and the endosomal
sorting of membrane proteins"
p(HGNC:BIN1) -> bp(GO:endocytosis)

SET Evidence = "Similar to PICALM, BIN1, due to its role
in endocytosis and trafficking, is implicated in APP metabolism [103]."
p(HGNC:BIN1) -> bp(GO:"amyloid precursor protein metabolic process")

SET Evidence = "Suppression of BIN1 disrupts cellular trafficking of BACE1 and reduces
BACE1 lysosomal degradation, leading to increased Aβ production [103]."
p(HGNC:BIN1) -> bp(GO:autophagy)
p(HGNC:BIN1) -| a(CHEBI:"amyloid-beta")

SET Evidence = "Higher expression of BIN1 has been reported in AD brains, and
suppression of BIN1 reduces tau toxicity, suggesting BIN1 involvement
in tau pathology, as well [104]."
p(HGNC:BIN1) pos path(MESH:"Alzheimer Disease")
p(HGNC:BIN1) pos path(MESH:Tauopathies)

SET Evidence = "In a more recent GWAS investigation, TREM2 (triggering receptor
expressed on myeloid cells 2) was identified as one of the markers
strongly associated with increased levels of tau and phosphorylated tau
in cerebrospinal fluid from AD patients [91]."
SET MeSHAnatomy = "Cerebrospinal Fluid"
SET MeSHDisease = "Alzheimer Disease"
p(HGNC:TREM2) pos p(HGNC:MAPT)
p(HGNC:TREM2) pos p(HGNC:MAPT,pmod(Ph))
UNSET MeSHAnatomy
UNSET MeSHDisease

SET Evidence = "Variants of TREM2 have been found to increase the risk of developing AD by approximately
three times [105,106], further validating it as a risk factor for AD."
p(HGNC:TREM2,var("?")) -> path(MESH:"Alzheimer Disease")

SET Evidence = "For example, Beclin 1 suppression results in impaired
microglial phagocytosis of Aβ and reduced recycling of TREM2 [108]."
SET Cell = "microglial cell"
p(HGNC:BECN1) -> bp(GO:phagocytosis)
UNSET Cell

SET Evidence = "Recent work by Ulland et al. has also discovered an additional function
of TREM2 in the maintenance of microglial macroautophagy and metabolism"
SET Cell = "microglial cell"
p(HGNC:TREM2) -> bp(GO:macroautophagy)
p(HGNC:TREM2) -> bp(GO:"metabolic process")
UNSET Cell

SET Evidence = "TREM2 deficiency in an AD mouse model results in suppressed
metabolic function in microglia through the dampening of the
mTOR signaling pathway, which subsequently elicits a compensatory
autophagic response to address the metabolic defect [109]."
SET MeSHDisease = "Alzheimer Disease"
SET Cell = "microglial cell"
p(HGNC:TREM2) -> bp(GO:"metabolic process")
p(HGNC:TREM2) -> act(complex(GO:"TOR complex"))
UNSET Cell
UNSET MeSHDisease

SET Evidence = "VPS35, one of the retromer-related genes identified from GWAS
datasets on AD [110], regulates TREM2’s function in microglia [111]."
SET Cell = "microglial cell"
p(HGNC:VPS35) reg act(p(HGNC:TREM2))
UNSET Cell

SET Evidence = "VPS35 mutations have been shown to disrupt macroautophagy
[113] and mitochondrial function [114] and are associated with AD
and PD [102,115]."
p(HGNC:VPS35,var("?")) -| bp(GO:macroautophagy)
p(HGNC:VPS35,var("?")) -| act(a(GO:mitochondrion))
p(HGNC:VPS35,var("?")) -- path(MESH:"Alzheimer Disease")
p(HGNC:VPS35,var("?")) -- path(MESH:"Parkinson Disease")

SET Evidence = "One intriguing molecule that interacts with VPS35 is
SORL1, a VPS10P-domain receptor protein that has been linked to autosomal
dominant early-onset AD [116,117]."
p(HGNC:VPS35) => complex(p(HGNC:SORL1),p(HGNC:VPS35))
p(HGNC:SORL1) -- path(MESH:"Alzheimer Disease")

SET Evidence = "Identified as a candidate
susceptibility gene for AD by GWAS [116], reduced level of SORL1 has
been consistently correlated with brain Aβ levels [118,119]."
p(HGNC:SORL1) neg a(CHEBI:"amyloid-beta")

SET Evidence = "Mitochondria are instrumental in the regulation of energy metabolism, and impairment in
mitochondrial function has been implicated in the pathogenesis of AD,
leading to the mitochondrial cascade hypothesis of AD [121]."
a(GO:mitochondrion) reg bp(GO:"energy homeostasis")
path(HBP:"mitochondrial dysfunction") -> path(MESH:"Alzheimer Disease")

SET Evidence = "Dysfunctional mitochondria are
critically harmful to cells, as this leads to decreased synthesis of cellular
ATP and accumulation of ROS, which further overburden and damage
other functional mitochondria."
path(HBP:"mitochondrial dysfunction") -| a(CHEBI:ATP)
path(HBP:"mitochondrial dysfunction") -> a(CHEBI:"reactive oxygen species")

SET Evidence = "Previous studies demonstrate impaired
mitochondrial function preceding the accumulation of hallmark proteins
in AD, such as Aβ [123,124] and tau [125]."
SET MeSHDisease = "Alzheimer Disease"
path(HBP:"mitochondrial dysfunction") -> a(CHEBI:"amyloid-beta")
path(HBP:"mitochondrial dysfunction") -> p(HGNC:MAPT)
UNSET MeSHDisease

SET Evidence = "Thus, as a quality control mechanism, mitophagy − a form of selective macroautophagy
that specifically targets mitochondria − occurs in response to damaged
or dysfunctional mitochondria in order to prevent mitochondrial bioenergetic deficits."
path(HBP:"mitochondrial dysfunction") -> bp(GO:mitophagy)

SET Evidence = "A recent study reported that mitophagy is robustly induced in AD brains and in
vitro models of mutant APP, accompanied with abnormal accumulation of depoloarized mitochondria [126]"
SET MeSHAnatomy = "Brain"
path(MESH:"Alzheimer Disease") -> bp(GO:mitophagy)
UNSET MeSHAnatomy

SET Evidence = "Altogether, as with proteinopathy, accumulation of
damaged or dysfunctional mitochondria is detrimental to the development of AD pathologies"
path(HBP:"mitochondrial dysfunction") -> path(MESH:"Alzheimer Disease")

SET Evidence = "PSEN1 M146L and A246E mutant cortical neurons have been shown to possess decreased
activation of the CLEAR (coordinated lysosomal expression and regulation)
gene network, as measured by a TFEB-driven luciferase assay,
consistent with a reduction in autophagic activity [131]."
p(HGNC:PSEN1,var("p.Met146Leu")) -| bp(GO:autophagy)
p(HGNC:PSEN1,var("p.Ala246Glu")) -| bp(GO:autophagy)

SET Evidence = "In a similar vein, PSEN1 A246E mutant cortical neurons have reduced mitophagy
compared to control neurons, which is associated more with decreased
lysosomal function rather than mitochondrial targeting [132]."
p(HGNC:PSEN1,var("p.Ala246Glu")) -| bp(GO:mitophagy)
p(HGNC:PSEN1,var("p.Ala246Glu")) -| act(a(GO:lysosome))

SET Evidence = "For example, in tau A152T iPSC-derived cortical neurons, total
and phosphorylated Tau levels are elevated, particularly the insoluble
forms [133], which is associated with decreases in UPS function as
measured by total polyubiquitinated proteins and an upregulation of
macroautophagy markers."
p(HGNC:MAPT,var("p.Ala152Thr")) pos p(HGNC:MAPT,pmod(Ph))
p(HGNC:MAPT,var("p.Ala152Thr")) -| bp(GO:"proteasome-mediated ubiquitin-dependent protein catabolic process")
p(HGNC:MAPT,var("p.Ala152Thr")) -> bp(GO:macroautophagy)

SET Evidence = "However, in another study, iPSC-derived tau
A152T and MAPT IVS 10+16 (a tau splice mutant) cortical neurons
had increased cell death in response to rapamycin treatment, although
basal cell death was ∼10 times higher in these tau mutants relative to
controls, making interpretation of the work difficult [134]."
composite(p(HGNC:MAPT,var("p.Ala152Thr")),a(CHEBI:sirolimus)) -> bp(GO:"cell death")

SET Evidence = "Finally, numerous studies using iPSC models have implicated
changes in macroautophagy pathways in Parkinson’s disease
[137–144], Gaucher disease [145], Niemann-Pick Type C1 disease
[146–148] and diseases affecting motor neurons, including ALS
[149,150], spinal and bulbar muscular atrophy (SBMA) [151], Brown-
Vialetto disease [152], Charcot-Marie-Tooth 2A [153] and hereditary spastic paraplegia [154]"
path(MESH:"Parkinson Disease") neg bp(GO:macroautophagy)
path(MESH:"Niemann-Pick Disease, Type C") neg bp(GO:macroautophagy)
path(MESH:"Amyotrophic Lateral Sclerosis") neg bp(GO:macroautophagy)
path(MESH:"Bulbo-Spinal Atrophy, X-Linked") neg bp(GO:macroautophagy)
path(MESH:"Spastic Paraplegia, Hereditary") neg bp(GO:macroautophagy)

SET Evidence = "Protein clearance in animal models has been successfully demonstrated
using several small molecules and drugs that enhance induction
of macroautophagy reduces AD-relevant pathology, including rapamycin
in 3xTGAD mice [32] and temsirolimus in P301S transgenic mice
[156] and trehalose in APP/PS1 and P301S MAPT transgenic mice [157,158]."
a(CHEBI:sirolimus) -> bp(GO:macroautophagy)
a(CHEBI:Temsirolimus) -> bp(GO:macroautophagy)
a(CHEBI:"alpha,alpha-trehalose") -> bp(GO:macroautophagy)

SET Evidence = "Methylene blue, a contrast agent that can reduce tau misfolding,
has also been shown to induce macroautophagy, as indicated
by elevated Beclin 1 and LC3-II levels and reduced tau and p62 levels in
organotypic neuronal cultures and a mouse model of FTD [159]"
a(CHEBI:"methylene blue") -| p(HGNC:MAPT,pmod(HBP:misfolding))
a(CHEBI:"methylene blue") -> bp(GO:macroautophagy)
a(CHEBI:"methylene blue") -> p(HGNC:BECN1)
a(CHEBI:"methylene blue") -> p(HGNC:MAP1LC3B)
a(CHEBI:"methylene blue") -| p(HGNC:MAPT)
a(CHEBI:"methylene blue") -| p(HGNC:SQSTM1)

SET Evidence = "Paclitaxel reversed Aβ-induced microtubule
disruption and restored autophagosomal transport in neurons
[161], while a similar compound, epothilone D/BMS-241027, reduced
tauopathy and improved cognition in P301S transgenic mice [162] although
the compound did not progress beyond Phase I clinical testing"
a(CHEBI:paclitaxel) -> a(GO:microtubule)
a(CHEBI:paclitaxel) -> tloc(a(GO:autophagosome),fromLoc(GO:"extracellular space"),toLoc(MESH:Neurons)))
a(CHEBI:epothilone) -| path(MESH:Tauopathies)
a(CHEBI:epothilone) -> bp(GO:cognition)
